AU6399500A - Treatment of liver disease and injury with cxc chemokines - Google Patents
Treatment of liver disease and injury with cxc chemokinesInfo
- Publication number
- AU6399500A AU6399500A AU63995/00A AU6399500A AU6399500A AU 6399500 A AU6399500 A AU 6399500A AU 63995/00 A AU63995/00 A AU 63995/00A AU 6399500 A AU6399500 A AU 6399500A AU 6399500 A AU6399500 A AU 6399500A
- Authority
- AU
- Australia
- Prior art keywords
- injury
- treatment
- liver disease
- cxc chemokines
- cxc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108050006947 CXC Chemokine Proteins 0.000 title 1
- 102000019388 CXC chemokine Human genes 0.000 title 1
- 206010067125 Liver injury Diseases 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14785599P | 1999-08-09 | 1999-08-09 | |
US60147855 | 1999-08-09 | ||
PCT/US2000/021306 WO2001010899A2 (en) | 1999-08-09 | 2000-08-04 | Treatment of liver disease and injury with cxc chemokines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6399500A true AU6399500A (en) | 2001-03-05 |
Family
ID=22523188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU63995/00A Abandoned AU6399500A (en) | 1999-08-09 | 2000-08-04 | Treatment of liver disease and injury with cxc chemokines |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6399500A (en) |
WO (1) | WO2001010899A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146970A0 (en) * | 2001-12-06 | 2002-08-14 | Yeda Res & Dev | Migration of haematopoietic stem cells and progenitor cells to the liver |
US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
GB201518151D0 (en) * | 2015-10-14 | 2015-11-25 | Univ Dublin | Method and compounds for treatment and prophylaxis of bleeding episodes |
CN105944085A (en) * | 2016-06-13 | 2016-09-21 | 浙江生创精准医疗科技有限公司 | Application of IL-6 or IL-6 and other cytokines to treatment of hepatic fibrosis |
CN105944086B (en) * | 2016-06-13 | 2017-08-25 | 浙江生创精准医疗科技有限公司 | IL 8 is independent or combines the purposes in treatment liver fibrosis with other cell factors |
CN105920579A (en) * | 2016-06-13 | 2016-09-07 | 浙江生创精准医疗科技有限公司 | Single application of GRO (growth-regulated oncogene) or joint application of GRO and other cytokines to treatment of hepatic fibrosis |
CN105944082B (en) * | 2016-06-13 | 2017-08-25 | 浙江生创精准医疗科技有限公司 | Osteoprotegerin is independent or combines the purposes in treatment liver fibrosis with other cell factors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
-
2000
- 2000-08-04 WO PCT/US2000/021306 patent/WO2001010899A2/en active Application Filing
- 2000-08-04 AU AU63995/00A patent/AU6399500A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001010899A2 (en) | 2001-02-15 |
WO2001010899A3 (en) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02004770A (en) | Therapeutic compositions and methods of use thereof. | |
IL144954A0 (en) | Quinazolines and therapeutic use thereof | |
AU2001275177A1 (en) | Cardiac disease treatment and device | |
AU2001281369A1 (en) | Cardiac disease treatment and device | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
AU4289100A (en) | Dihydropyrimidines and their use in the treatment of hepatitis | |
AU7067200A (en) | Skin care compositions and treatments | |
AU5618501A (en) | Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis | |
AU715620C (en) | Therapeutic methods and uses | |
AU2300001A (en) | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease | |
AU2001270484A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
AU6399500A (en) | Treatment of liver disease and injury with cxc chemokines | |
HUP0003244A2 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof | |
AU7134700A (en) | Maize msi polynucleotides and methods of use | |
EP1173189A4 (en) | Asialocytokines and treatment of liver disease | |
AU1646201A (en) | Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock | |
AU3971800A (en) | 2-alkoxy-cyclobutene-3,4-dione derivatives, preparation and therapeutic use thereof | |
AU1654001A (en) | Improved physical and thermal treatment of waste | |
AU2595201A (en) | Antiviral therapeutic composition and treatment | |
IL143795A0 (en) | Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections | |
EP1167527A4 (en) | Processed human chemokines PHC-1 and PHC-2 | |
AU2224800A (en) | Compositions and methods for the treatment of tumor | |
AUPQ267099A0 (en) | Psoriasis and exzema treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |